PFEPFIZER INC

NYSE pfizer.com


$ 29.61 $ 1.04 (3.64 %)    

Wednesday, 22-May-2024 15:59:58 EDT
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 29.6
$ 28.45
$ 0.00 x 0
$ 0.00 x 0
$ 28.42 - $ 29.63
$ 24.83 - $ 38.23
46,109,194
na
168.63B
$ 0.58
nm
TBD
na
na ($ 0.06)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-08-2023 10-01-2023 10-Q
4 08-09-2023 07-02-2023 10-Q
5 05-10-2023 04-02-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-09-2022 10-02-2022 10-Q
8 08-10-2022 07-03-2022 10-Q
9 05-11-2022 04-03-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-12-2021 10-03-2021 10-Q
12 08-12-2021 07-04-2021 10-Q
13 05-13-2021 04-04-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-27-2020 10-Q
16 08-06-2020 06-28-2020 10-Q
17 05-07-2020 03-29-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-07-2019 09-29-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 07-01-2018 10-Q
25 05-10-2018 04-01-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-09-2017 10-01-2017 10-Q
28 08-10-2017 07-02-2017 10-Q
29 05-11-2017 04-02-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-10-2016 10-02-2016 10-Q
32 08-11-2016 07-03-2016 10-Q
33 05-12-2016 04-03-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-05-2015 09-27-2015 10-Q
36 08-06-2015 06-28-2015 10-Q
37 05-07-2015 03-29-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-06-2014 09-28-2014 10-Q
40 08-07-2014 06-29-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 experts-predict-rise-in-covid-19-cases-vaccine-stocks-climb

Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covi...

 pfizer-says-in-q2-2024-it-is-launching-a-multi-tear-program-to-reduce-our-cost-of-goods-sold-first-phase-of-multi-year-program-to-reduce-cost-of-goods-sold-is-expected-to-deliver-savings-of-15b-by-end-of-2027-costs-will-be-recorded-primarily-in-2024-with-cash-outlays-expected-in-2025-and-2026-one-time-costs-to-achieve-savings-associated-with-first-phase-of-program-are-expected-to-be-about-17b

- Reuters

Core News & Articles

https://www.nbcnews.com/now/video/disease-experts-predict-a-small-rise-in-covid-cases-this-summer-211393605953 Disease experts ...

 hospira-inc-issues-a-voluntary-nationwide-recall-for-buprenorphine-hydrochloride-injection-carpuject-units-and-labetalol-hydrochloride-injection-usp-carpuject-units-due-to-the-potential-for-incomplete-crimp-seals---press-release

https://www.pfizer.com/news/announcements/hospira-inc-issues-voluntary-nationwide-recall-buprenorphine-hydrochloride

 gsk-concealed-risk-associated-with-discontinued-heart-burn-drug-zantac-whistleblower-lawsuit-claims

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. Thi...

 pfizer-wins-1075m-verdict-against-astrazeneca-over-cancer-drug-patent-dispute

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infri...

 pfizer-unusual-options-activity
Pfizer Unusual Options Activity
05/20/2024 18:01:06

Core News & Articles

https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0.pdf 

 cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...

 pfizer-disappointed-about-1st-instance-decision-by-opposition-division-of-european-patent-office-to-maintain-modernas-european-patent-ep3590949-b1-says-will-consider-all-legal-options-and-may-appeal-decision-by-european-patent-office

-Reuters

 european-patent-office-sides-with-moderna-in-covid-19-vaccine-patent-dispute-with-pfizerbiontech

Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents.

Core News & Articles

https://www.ft.com/content/50c5078c-c9f0-4b35-b916-3475b641c773Moderna has won a case at the European Patent Office in its disp...

 gsk-completely-exits-sensodyne-toothpaste-maker-haleon-in-16b-sale

GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advi...

 pfizer-astrazeneca-sanofi-and-mainz-biomed-to-uplevel-europes-pharma-game

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...

Core News & Articles

After six months of additional follow-up, these data are consistent with data presented at the San Antonio Breast Cancer Sympos...

 pfizer-settles-zantac-lawsuits-agrees-to-250m-settlement-to-reduce-liability-report

In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc has agreed to pay up to $250 m...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION